Taipei, Nov. 22 (CNA) A new cancer drug under development could begin Phase 1 testing in humans in 2022 after it obtained good results in treating eight types of cancers in tests on animals, Taiwan's National National Health Research Institutes (NHRI) announced Monday.
A new cancer drug under development could begin phase 1 testing in humans next year after it obtained good results in treating eight types of cancers in animal tests, the National Health Research Institutes (NHRI) announced yesterday.
Hsieh Hsing-pang (謝興邦), a researcher at the NHRI’s Institute of Biotechnology and Pharmaceutical Research (IBPR), said at a media briefing that 40 late-stage cancer patients who have not been helped by any available treatment, but are still in decent physical condition, are to be recruited for phase 1 clinical trials next year.
The new drug, known as DBPR144, is a small molecule known as a